View Older Stories View More Recent Stories

Dec 12, 2022 08:30AM CSL Announces Closing of Global Collaboration and Licensing Agreement with Arcturus Therapeutics
Dec 10, 2022 10:00AM CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treat
Nov 22, 2022 03:59PM U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
Nov 2, 2022 06:30PM Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
Nov 2, 2022 07:17AM Arcturus Therapeutics (ARCT) Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Nov 1, 2022 06:05PM Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Nov 1, 2022 06:00PM CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
Oct 6, 2022 12:00PM CSL Seqirus Announces U.S. Government Award to Manufacture and Clinically Assess Influenza A(H5N8) Pre-Pandemic Vaccine
Oct 5, 2022 08:30AM CSL Announces Positive Preclinical Data for Self-Amplifying Messenger RNA (sa-mRNA) Influenza Vaccine Candidates
Sep 26, 2022 08:00AM New Data at OPTIONS XI Conference Highlight Burden of Seasonal Influenza on Health Systems and the Need for Increased Vaccination Rates
Sep 26, 2022 08:00AM New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems
Sep 13, 2022 10:00AM CSL presents new research and development center in Marburg, Germany
Sep 13, 2022 08:00AM CSL Seqirus to Highlight Commitment to Influenza Protection with More than 20 Data Presentations at OPTIONS XI
Aug 19, 2022 01:00AM Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Aug 17, 2022 11:00AM CSL Announces Positive Top-Line Phase 3 Results for Garadacimab as Preventive Treatment in Patients with Hereditary Angioedema (HAE)
Aug 16, 2022 06:45PM CSL announces carbon emissions reduction targets
Aug 10, 2022 10:30AM CSL LAUNCHES NEW UNIFIED GLOBAL BRAND IDENTITY
Aug 4, 2022 03:07PM CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology
Jul 11, 2022 08:00AM Seqirus Begins Shipping Portfolio of Innovative Influenza Vaccines for the 2022/23 U.S. Season
Jun 22, 2022 05:30PM CDC Advisory Committee Includes FLUAD® QUADRIVALENT as a Preferentially Recommended Influenza Vaccine for Adults 65 and Older
Jun 9, 2022 08:00AM Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with Hemophilia
Jun 6, 2022 08:30AM Seqirus Completes $156 Million Expansion to Holly Springs Manufacturing Facility, Optimizing Global Manufacturing Capabilities for Seasonal and Pandemic Influenza Vaccines
Jun 2, 2022 08:30AM Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready
May 24, 2022 08:00AM FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
Apr 28, 2022 08:00AM CSL Behring Donates 500 Million International Units of Coagulation Factor Replacement Therapy to the World Federation of Hemophilia Humanitarian Aid Program to Help Those Living with Bleeding Disorder
Mar 28, 2022 02:13AM European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Mar 10, 2022 03:16PM Statement on U.S. FDA Clearance of Plasma Collection Technology in Terumo Blood and Cell Technologies Collaboration with CSL Plasma
Feb 25, 2022 08:30AM Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
Feb 22, 2022 09:05AM CSL Plasma Makes $125,000 Donation to American Red Cross for Disaster Relief in U.S. Communities
Feb 7, 2022 08:30AM Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
Feb 4, 2022 10:20AM Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
Dec 15, 2021 07:33AM CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
Dec 15, 2021 07:30AM EMA Grants Accelerated Assessment for CSL Behring's Haemophilia B Gene Therapy
Dec 9, 2021 07:07AM uniQure (QURE), CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
Dec 9, 2021 07:05AM uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
Dec 7, 2021 01:00PM New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults
Nov 23, 2021 08:30AM Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adjuvanted, Cell-Based Pandemic Influenza Vaccine
Sep 9, 2021 08:30AM Urban League of Philadelphia Names CSL's Elizabeth Walker to Board of Directors
Sep 4, 2021 04:00AM CSL Behring Underscores its Commitment to Respiratory Patients with Strong Focus on Research
Aug 9, 2021 09:20AM The European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force Has Strongly Recommended Subcutaneous Immunoglobulin (SCIg) for CIDP Maintenance Treatment
Aug 3, 2021 09:10AM FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience
Jun 8, 2021 09:00AM Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) To Be Covered Under Medicare Part B Effective July 18, Improving Access and Reducing Out-of-Pocket Costs for CIDP Patients
May 16, 2021 01:15PM New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
May 14, 2021 07:30AM Lyfebulb and CSL Behring Announce the Winner of the 2021 Transplant Innovation Challenge
May 6, 2021 07:05AM CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
Apr 29, 2021 08:30AM Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) Label Update Provides New Dosing Guidelines for Physicians, Allowing for Greater Flexibility in Treating CIDP Patients
Mar 24, 2021 12:00PM Lyfebulb and CSL Behring Announce the Finalists for the 2021 Transplant Innovation Challenge
Jan 25, 2021 08:45AM Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients
Jan 7, 2021 09:00AM Lyfebulb Announces Call-to-Action for Submissions to the 2021 Innovation Challenge: Thriving with Transplantation
Nov 19, 2020 07:00AM New Harris Poll Survey Finds Vast Majority of People Living with Hereditary Angioedema (HAE) Value Efficacy and Specific Correction of C1-INH Deficiency When Choosing an HAE Therapy
View More Recent Stories View Older Stories